Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs).
The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical significance. The primary endpoint was the time to catheter failure, with Mino-Lok achieving superior results compared to the control arm. The next steps include FDA submission and a Type B meeting.
Mino-Lok® could potentially set a new standard of care by offering a non-invasive alternative to catheter removal and replacement. The Phase 3 trial data indicates that Mino-Lok® is well-tolerated and effective, demonstrating a substantial delay in catheter failure events compared to the control group.
In addition, BD is addressing supply issues for blood culture vials, and CorMedix has launched DefenCath® for outpatient dialysis centers. Vir Biotechnology received FDA clearance for its hepatitis delta treatment combination, highlighting the ongoing innovations in the infection treatment market.
- Citius Pharmaceuticals reported positive topline data from the Phase 3 study of Mino-Lok® in CRBSIs.
- Mino-Lok® met primary and secondary endpoints with statistical significance in the Phase 3 trial.
- Mino-Lok® demonstrated overall treatment success in 57.1% of patients compared to 37.7% in the control arm.
- Mino-Lok® could potentially set a new standard of care, offering a non-invasive alternative to catheter removal and replacement.
- None.
Insights
The recent developments in the bloodstream infections (BSIs) treatment market, particularly the advancements made by Citius Pharmaceuticals, have noteworthy implications for both the healthcare industry and investors. The positive topline data from the Phase 3 study of Mino-Lok® underscore its potential as a groundbreaking therapy for catheter-related bloodstream infections (CRBSIs). This study met its primary and secondary endpoints with statistical significance, indicating a high degree of efficacy. Meeting these endpoints signifies that the drug shows promise in its intended use, which could lead to FDA approval. If approved, Mino-Lok would be the first and only FDA-approved treatment that salvages central venous catheters, representing a significant advancement in patient care.
The market adoption of Mino-Lok could be substantial given the high incidence of CRBSIs and the serious complications associated with catheter removal and replacement. This would not only benefit patients by providing a less invasive treatment option but also potentially reduce healthcare costs associated with managing these infections. From a clinical perspective, the drug's ability to delay catheter failure and improve overall treatment success rates positions it favorably compared to existing treatments.
For investors, Citius Pharmaceuticals' advancements with Mino-Lok® provide a promising outlook. The positive Phase 3 trial results indicate a strong likelihood of FDA approval, which could significantly enhance the company's market position. FDA approval typically leads to increased market valuation due to the potential for revenue growth. If Mino-Lok is approved, it would fill a critical need in the treatment of CRBSIs, potentially capturing a significant share of this market.
Financially, the success of Mino-Lok could lead to substantial revenue streams, considering the high demand for effective treatments for bloodstream infections.
The potential market impact of Mino-Lok® is significant. With a strong Phase 3 data set, Mino-Lok could address a large unmet need in the treatment of catheter-related bloodstream infections. Considering the high mortality rates associated with BSIs, there is a substantial demand for innovative solutions that improve patient outcomes. Mino-Lok's ability to salvage central venous catheters without removal and replacement offers a unique value proposition that could drive its rapid adoption in clinical settings.
Furthermore, the healthcare industry's ongoing focus on cost reduction and improving patient care outcomes aligns well with the benefits offered by Mino-Lok. The economic benefits of reducing catheter removal and replacement procedures—which can lead to significant healthcare savings—are likely to further support the drug's market penetration. Overall, Mino-Lok's potential to set a new standard of care could not only benefit patients but also position Citius favorably in the competitive landscape of infection treatments.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 11, 2024) - Investorideas.com, a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates.
"Bloodstream infections (BSI) are a growing threat to public health worldwide. The 2 million cases of BSIs that occur annually in North America and Europe are associated with 250,000 deaths, making BSIs the leading cause of mortality from infection", says a recent report in the Journal of Clinical Microbiology.
Read the full article on Investorideas.com
https://www.investorideas.com/news/2024/biotech/07112Bloodstream-Infections.asp
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) just announced expected milestones in the second half of calendar 2024 and recapped key achievements year-to-date.
Citius reported it has significantly advanced its two late-stage product candidates in the first six months of 2024, and expects several key milestones in the near term.
Citius recently announced positive topline data from the Phase 3 study of Mino-Lok® in catheter-related bloodstream infections (CRBSIs). Primary and secondary endpoints were met with statistical significance.
Next steps for the Mino-Lok program are to prepare a submission to the U.S. Food and Drug Administration (FDA) and schedule a Type B meeting.
Mino-Lok (MLT), a novel antibiotic lock solution that combines minocycline, ethanol and edetate disodium, is designed to treat patients with catheter-related blood stream infections. Citius licensed Mino-Lok from an affiliate of The University of Texas MD Anderson Cancer Center. Mino-Lok is designed to offer an alternative to removing and replacing a central venous catheter (CVC), which may lead to a reduction in serious adverse events and cost savings to the healthcare system. If approved, Mino-Lok would be the first and only FDA-approved treatment that salvages central venous catheters that cause central line-related blood stream infections.
In late May, Citius announced positive topline results of its pivotal Phase 3 clinical trial of Mino-Lok®, a novel antibiotic lock solution designed to salvage catheters in patients with central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The study met its primary endpoint with a statistically significant improvement in the time to failure event in patients receiving Mino-Lok compared to Control arm patients receiving clinician-directed anti-infective lock solution. The data demonstrate that Mino-Lok is well-tolerated.
"We are extremely pleased by the strong results of the trial, which demonstrate the safety and efficacy of Mino-Lok in preserving indwelling catheters in patients with bloodstream infections. The data indicate, with a high degree of statistical significance, that Mino-Lok outperforms anti-infective lock solutions utilized in patients with CLABSI or CRBSI in the study's control arm. We believe Mino-Lok could potentially set a new standard of care (SOC) as an adjunct therapy in the treatment of patients with bloodstream infections. This therapy offers a non-invasive treatment option compared to catheter removal and replacement," stated Leonard Mazur, Chairman and Chief Executive Officer of Citius.
"We look forward to engaging with the US Food and Drug Administration (FDA) to determine the optimal path forward for Mino-Lok. Our focus remains on improving outcomes for patients and offering a much-needed alternative to the current practice of catheter removal and replacement," added Mazur.
Mino-Lok Phase 3 Trial Design
MDA 2013-0039 (NCT02901717) is a completed Phase 3 multicenter, randomized, open-label, active-controlled assessor-blinded trial conducted to evaluate the safety and efficacy of Mino-Lok as an adjunctive therapy to systemic anti-infectives for the treatment of catheter-related bloodstream infections (CRBSI) and central line-associated infections (CLABSI).
More from the news: A total of 241 patients in the U.S. and India, with an indwelling central venous catheter before the onset of a bloodstream infection, were randomized in a 1:1 ratio to receive either Mino-Lok or SOC site-specific anti-infective lock solution plus SOC systemic antibiotics. Enrollment was not limited to patients with specific types of catheters. Patients in the Mino-Lok arm received one Mino-Lok dose daily with a dwell time of two to four hours for a total of seven doses over a period of up to 15 days.
The primary endpoint for this study is the time to a catheter failure event between randomization and test of cure (TOC) at six weeks, measured in days following randomization. Additional secondary outcome measures include overall success, microbiological eradication, and clinical cure, among others.
For subjects in the Control arm, the investigator determined the antibiotic used in the lock, dose, dwell time, and number of days of administration based on institutional standards or Infectious Diseases Society of America (IDSA) guidelines.
TOPLINE RESULTS
Efficacy:
The primary endpoint in the study was time to catheter failure between randomization and six-weeks following the first dose of Mino-Lok or SOC lock solution. Catheter failure was defined as the inability to administer study lock solution, catheter removal for any infection-related reason (including worsening clinical signs and symptoms or persistence or recurrence of baseline pathogen, or new infection), and all-cause mortality.
Results of blinded-assessor clinical outcome analyses in all randomized patients demonstrated that Mino-Lok achieved its primary endpoint:
Time to catheter failure events in patients receiving Mino-Lok therapy occurred substantially later than in patients in the Control arm (p value = 0.0006)
Median time-to-failure (MTF) of Control arm: 33 days;
Median time-to-failure (MTF) of Mino-Lok arm: MTF exceeded the time the patients were on trial and therefore not estimable (NE);
The hazard ratio of this study was 0.53
The critical secondary endpoints included the proportion of patients at six weeks with overall treatment success including no catheter failure, clinical cure (absence of baseline clinical signs and symptoms of infection or improvement of clinical signs and symptoms such that no additional therapy was necessary), or microbiological eradication (absence of the baseline pathogen).
Results in all randomized patients who received at least one dose of study lock solution demonstrate overall treatment success in
Safety:
Mino-Lok is designed for intracatheter instillation and is not for intravenous injection or systemic circulation.
No serious adverse events were drug-related
Serious adverse events occurred in
BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following statement related to a US FDA letter to health care providers regarding the supply of blood culture vials:
From the news: Nikos Pavlidis, worldwide president of BD Diagnostic Solutions said, "BD is experiencing reduced availability of blood culture vials from our supplier. We understand the critical role that blood culture testing plays in diagnosing and treating infections and are taking all available measures to address this important issue, including providing the supplier our manufacturing expertise, using air shipments, modifying BD manufacturing schedules for rapid production, and collaborating with the U.S. Food and Drug Administration to review all potential options to mitigate delays in supply. As an additional stopgap measure, our former supplier of glass vials will restart production to help fill the intermittent gap in supply.
"We take our responsibility to support health care providers and patients very seriously and, while we are able to meet the majority of global demand, we are taking all available measures to address this important issue. BD BACTEC™ blood culture vials are being allocated manually so we can best mitigate any impact to patient care. Customers have been advised to prioritize the use of blood culture vials based on clinical needs and following guidelines, such as the most recent update from the Infectious Disease and Society of America and/or the World Health Organization.
"While this supplier issue is not expected to have a material financial impact on BD, we are fully focused on returning the supply of blood culture vials to normal levels."
CorMedix Inc., a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, recently announced that it has commenced commercialization of DefenCath® (taurolidine and heparin) to outpatient dialysis centers and vascular access clinics where patients receive outpatient dialysis and catheter placement services. The outpatient launch coincides with the effective date of July 1st for outpatient reimbursement of DefenCath® as directed by the Center for Medicare & Medicaid Services (CMS).
Late last year, CorMedix announced that the US Food and Drug Administration (FDA) had approved DefenCath® (taurolidine and heparin) catheter lock solution (CLS) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). DefenCath® is the first and only FDA-approved antimicrobial CLS in the U.S. and was shown to reduce the risk of CRBSIs by up to
Vir Biotechnology, Inc., an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application and granted Fast Track designation for the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta infection. Tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, are currently being evaluated in the Company's Phase 2 SOLSTICE hepatitis delta clinical trial, with complete 24-week treatment data on track to be reported in the fourth quarter.
"The IND clearance and Fast Track designation from the FDA, along with the encouraging preliminary data from our Phase 2 hepatitis delta trial, underscore the potential of tobevibart and elebsiran to transform the treatment landscape for people living with this severe and life-threatening disease," said Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. "We are committed to working closely with health authorities to bring this potential groundbreaking treatment to patients as quickly as possible, addressing a critical unmet medical need."
Some of the biggest pharma companies including Abbott Laboratories, are grabbing market share in the blood infections testing market, estimated at over 875 Million in 2023.
From testing to treatments, the life threatening bloodstream infection market is seeing breakthroughs in technology to answer the call.
Research and find more biotech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
About Investorideas.com - Big Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.
Disclaimer/Disclosure: This news article featuring Citius Pharmaceuticals, Inc. (CTXR) a paid for news release creation and dissemination on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/216129
FAQ
What recent advancements has Citius Pharmaceuticals (CTXR) made in treating bloodstream infections?
What is the significance of the Phase 3 trial results for Mino-Lok®?
What are the next steps for Citius Pharmaceuticals (CTXR) after the Phase 3 trial of Mino-Lok®?
How did Mino-Lok® perform in terms of overall treatment success in the Phase 3 trial?
What is the potential impact of Mino-Lok® on the current standard of care for bloodstream infections?
